Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Compare this stock

HLN Stock Report Card

$

VolatilityTechnicalsProfitPerformanceEarnings

77%

Performance

Score:

100/100

HLN returned 20.18% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Technicals

Score:

50/100

HLN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

Score:

100/100

HLN has missed earnings 1 times in the last 20 quarters.

Profit

Score:

72/100

Out of the last 9 quarters, HLN has had 9 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

Score:

57/100

HLN has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / HLN
Healthcare
Drug Manufacturers - Specialty & Generic
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.